{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:28:21Z","timestamp":1771259301849,"version":"3.50.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"DOI":"10.1093\/ibd\/izaf028","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T04:19:34Z","timestamp":1738210774000},"page":"2045-2046","source":"Crossref","is-referenced-by-count":1,"title":["Letter to the Editor: Microscopic Colitis after Ocrelizumab for Multiple Sclerosis"],"prefix":"10.1093","volume":"31","author":[{"given":"Mark","family":"Chatto","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, University Hospital, Western University , 339 Windermere Rd, London, ON N6A 5A5 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-1284","authenticated-orcid":false,"given":"Cady","family":"Zeman-Pocrnich","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University Hospital, Western University , 339 Windermere Rd, London, ON N6A 5A5 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Biostatistics & Epidemiology, University Hospital, Western University , 339 Windermere Rd, London, ON N6A 5A5 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"10","key":"2025070803365008700_CIT0001","doi-asserted-by":"publisher","first-page":"S913","DOI":"10.14309\/01.ajg.0000709112.86831.18","article-title":"S1766 Ocrelizumab-induced colitis: a case report","volume":"115","author":"Tuqan","year":"2020","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"July","key":"2025070803365008700_CIT0002","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.msard.2023.104763","article-title":"Anti-CD20 monoclonal antibody (mAb) therapy and colitis: a case series and review","volume":"75","author":"Tolaymat","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"2025070803365008700_CIT0003","doi-asserted-by":"publisher","first-page":"e252140","DOI":"10.1136\/bcr-2022-252140","article-title":"Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis","volume":"15","author":"Malloy","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"10","key":"2025070803365008700_CIT0004","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1177\/13524585231195854","article-title":"Immune-mediated colitis associated with ocrelizumab: a new safety risk","volume":"29","author":"Kim","year":"2023","journal-title":"Mult Scler."},{"issue":"6","key":"2025070803365008700_CIT0005","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1093\/ibd\/izaa057","article-title":"First case of refractory colitis caused by ocrelizumab","volume":"26","author":"Sunjaya","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2025070803365008700_CIT0006","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.gastro.2019.11.043","article-title":"P096 De novo colitis after ocrelizumab therapy","volume":"158","author":"Akram","year":"2020","journal-title":"Gastroenterology."},{"issue":"10","key":"2025070803365008700_CIT0007","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1177\/13524585231195853","article-title":"Colitis in ocrelizumab-treated patients: the dilemma of causation versus association in immune-mediated iatrogenicity","volume":"29","author":"Abboud","year":"2023","journal-title":"Mult Scler."},{"issue":"1","key":"2025070803365008700_CIT0008","doi-asserted-by":"publisher","first-page":"e00742","DOI":"10.14309\/crj.0000000000000742","article-title":"Severe ocrelizumab-induced enterocolitis treated successfully with ustekinumab","volume":"9","author":"Shah","year":"2022","journal-title":"ACG Case Rep J"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf028\/61791391\/izaf028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/2045\/61791391\/izaf028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/2045\/61791391\/izaf028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T07:36:57Z","timestamp":1751960217000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/7\/2045\/8005036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":8,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf028","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,2,7]]}}}